Drug price in­creas­es lay­ered over decades: AARP analy­sis shows how list prices can rise by more than 700%

A new AARP analy­sis re­leased Thurs­day shows how list prices for the 25 top Medicare Part D drugs in­creased by an av­er­age of 226% since they first en­tered the mar­ket, mak­ing the need clear for the up­com­ing gov­ern­ment drug price ne­go­ti­a­tions and on­go­ing in­fla­tion-re­lat­ed re­bates, the re­tirees’ group said.

The find­ings from the re­port, which au­thor and AARP drug pol­i­cy prin­ci­pal Leigh Purvis said “serves as a wake-up call,” shows how all but one of the top 25 drugs’ life­time price in­creas­es great­ly ex­ceed­ed the rate of in­fla­tion, adding fu­el to the fire around the need for ne­go­ti­a­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER